Dublin, Oct. 29, 2025 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering.
The Global Cancer Immunotherapy Market stood at USD 105.7 billion in 2024 and is expected to grow to USD 254.6 billion by the year 2033 at a CAGR of 10.26% from 2025 to 2033. This growth is being fueled by the growing incidence of cancer, research on targeted therapies, growing awareness regarding the advantages of immunotherapy, and increased research and development efforts on innovative therapy options that increase patient survival and outcomes.
Growth Drivers in the Cancer Immunotherapy Market
Increasing Global Cancer Incidence
The increasing incidence of cancer worldwide is one of the main drivers of demand for immunotherapy therapies. Cancer is one of the most common causes of death globally, according to the WHO, with cases predicted to increase dramatically over the next few decades. The trend has been driving more investment in innovative and effective treatments, including immunotherapy, which provides targeted, less toxic treatment. Governments and healthcare organizations are also focusing on early detection and high-tech therapies, further driving market growth. The increased burden of disease still calls for new treatment options worldwide. An estimated 20 million new cancer cases and 9.7 million deaths occurred in 2022. The number of individuals who survived for 5 years after having cancer was estimated at 53.5 million. Approximately 1 in 5 individuals get cancer during their lifetime, around 1 in 9 men and 1 in 12 women succumb to the disease.
Technological Advancements and Innovation
Innovations and rapid developments in biotechnology and immuno-oncology have led to better and more tailored cancer immunotherapies. Methods like CAR T-cell therapy, immune checkpoint inhibitors, and next-generation monoclonal antibodies have significantly improved treatment outcomes. These advancements not only increase survival rates but decrease relapse rates as well. The incorporation of artificial intelligence into drug discovery and biomarker analysis has speeded up research and development, which has made immunotherapy more affordable. Ongoing breakthroughs will further enlarge the market with new, highly targeted cancer-fighting treatments. Nov 2024, India becomes the third nation, following China and the US, to gain access to the next-generation PD-1 inhibitor Toripalimab, which, in combination with regular chemotherapy, has demonstrated a 48% decrease in the risk of disease progression or death from nasopharyngeal carcinoma.
Increasing Research & Development Funding
Increased government and private funds allocated for cancer research have greatly accelerated the growth of immunotherapies. Many biotech firms and pharmaceuticals are in partnership with research institutes to discover new immuno-oncology therapies. Such funds cover preclinical studies, clinical trials, and regulations, enabling quicker product launches. Global cancer organizations and advocacy groups also actively work towards awareness and donations, which has encouraged innovation. With increased investments in innovative cancer treatment technologies, the immunotherapy products pipeline keeps growing. In April 2024, the Irish government invested more than 50 million euros in the treatment of cancer and 37.6 million euros in research on cancer as part of the National Cancer Strategy. The existence of corporations such as Bayer AG, Astrazeneca, and Immunogen has also added to market expansion.
Challenges in the Cancer Immunotherapy Market
High Cost of Treatment
Even though it is effective, the high price of cancer immunotherapy is a big obstacle, particularly in developing nations. Therapies like CAR T-cell therapy can be very expensive, costing hundreds of thousands of dollars, and thus restrict patient access. The pricing also puts pressure on public healthcare systems and insurance companies. Moreover, the cost of research, clinical trials, and regulatory affairs adds to the end-user pricing. The absence of uniform reimbursement policies in different regions worsens the cost burden, deterring the use of immunotherapy despite its therapeutic value.
Variable Patient Response and Side Effects
Cancer patients do not all respond well to immunotherapy, with variable treatment outcomes. Some have minimal or no benefit, while others will experience toxic immune-related adverse effects like inflammation, autoimmune responses, or organ toxicity. This uncertainty in treatment response creates challenges in the standardization of therapy. Furthermore, the intricacy of determining the right biomarkers for patient selection further restricts the universal use of immunotherapies. This has prompted the demand for companion diagnostics and customized treatment protocols.
Cancer Immunomodulators Market
Cancer immunomodulators are a significant growth-driving segment within immunotherapy. These drugs affect the immune response to cancer by boosting the natural ability of the body to fight tumors. Commonly used immunomodulators are cytokines, interleukins, and interferons. They have greatest efficacy in melanoma and hematological cancers. As clinical performance continues to achieve success, global demand for immunomodulators has increased sharply. Biopharmaceutical firms are heavily investing in the creation of next-generation immunomodulators with enhanced efficacy and reduced side effects. With advancements in research and the introduction of new delivery mechanisms, the immunomodulators segment is set to experience steady growth.
Cancer Monoclonal Antibodies Market
Monoclonal antibodies are among the most commonly applied immunotherapies in oncology. These engineered molecules in the laboratory specifically bind to antigens found on cancer cells, allowing the immune system to kill them more effectively. Drugs like trastuzumab (breast cancer) and rituximab (lymphoma) have shown excellent efficacy. Their increasing application in a variety of cancer types, coupled with ongoing R&D to make them more specific and less prone to side effects, is driving market growth. Biosimilars are also increasing patient access, especially in cost-conscious markets. With each new target discovery, the monoclonal antibodies market will grow.
Lung Cancer Immunotherapy Market
Lung cancer, the most prevalent and fatal cancer worldwide, has seen a major trend towards immunotherapy as an initial treatment. Immune checkpoint inhibitors such as pembrolizumab are now standard therapy for non-small cell lung cancer (NSCLC). Immunotherapies enhance survival rates and provide options for chemotherapy-resistant patients. Given the heavy burden of lung cancer worldwide, research into new combinations of immunotherapies goes on. Moreover, rates of smoking-induced cancer in emerging nations are rising, expanding the market base. Government policies promoting early detection and novel treatment solutions further drive the growth of this segment.
Breast Cancer Immunotherapy Market
Breast cancer immunotherapy is picking up pace with the discovery of immune checkpoint inhibitors and monoclonal antibodies. Immunotherapies such as atezolizumab have demonstrated potential, particularly in triple-negative breast cancer (TNBC), a type hard to treat with conventional therapies. The integration of immunotherapy with chemotherapy or targeted therapy is being investigated to enhance effectiveness. Since breast cancer is one of the leading cancers diagnosed among women globally, demand for new treatments is substantial. Clinical trials and regulatory clearances in the pipeline are anticipated to bolster this market segment tremendously in the years to come.
Colorectal Cancer Immunotherapy Market
Colorectal cancer immunotherapy is being incorporated into treatment protocols more and more, especially for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) patients. Agents nivolumab and pembrolizumab have shown better results in these populations. For the general population of colorectal cancer patients, though, immunotherapy remains struggling with efficacy. Studies are working towards overcoming resistance pathways and improving T-cell infiltration into tumors. With colorectal cancer one of the major causes of cancer death globally, there remains great potential for expansion in this category.
Cancer Immunotherapy Cancer Research Center Market
Cancer research centers are at the forefront in developing immunotherapy. The Dana-Farber Cancer Institute, MD Anderson Cancer Center, and Europe's Institut Gustave Roussy are among major global leaders in immuno-oncology innovation. These facilities not only carry out advanced research but also engage in multinational clinical trials and train experts in new therapies. Partnerships between academic institutions and biotech firms facilitate quick development and commercialization of new treatments. With more government and philanthropic support, cancer research facilities play a crucial role in bringing basic research to clinical practice, propelling the immunotherapy market growth.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2024-2033 |
| Estimated Market Value (USD) in 2024 | $105.7 Billion |
| Forecasted Market Value (USD) by 2033 | $254.6 Billion |
| Compound Annual Growth Rate | 10.2% |
| Regions Covered | Global |
Key Topics Covered
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Drivers
4.2 Restraints
5. Global Cancer Immunotherapy Market
6. Market Share Analysis
6.1 By Products
6.2 By Application
6.3 By End User
6.4 By Countries
7. Products
7.1 Monoclonal Antibodies
7.2 Immunomodulators
7.3 Cancer Vaccines
8. Application
8.1 Lung Cancer
8.2 Breast Cancer
8.3 Colorectal Cancer
8.4 Melanoma
8.5 Prostate Cancer
8.6 Head & Neck Cancer
8.7 Others
9. End Users
9.1 Hospital
9.2 Cancer Research Center
9.3 Clinics
10. Countries
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 Germany
10.2.2 United Kingdom
10.2.3 France
10.2.4 Italy
10.2.5 Spain
10.2.6 Switzerland
10.3 Asia-Pacific
10.3.1 Japan
10.3.2 China
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Indonesia
10.4 Latin America
10.4.1 Brazil
10.4.2 Argentina
10.4.3 Mexico
10.5 Middle East & Africa
10.5.1 South Africa
10.5.2 Saudi Arabia
10.5.3 United Arab Emirates
10.6 Rest of World
11. Porter's Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Key Players
13.1 Amgen Inc.
13.2 AstraZeneca
13.3 Bayer AG
13.4 Bristol-Myers Squibb Company
13.5 Pfizer Inc.
13.6 Novarts AG
13.7 Johnson & Johnson
13.8 Eli Lily Comapny
13.9 Seattle Genetics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/72l8e4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
